This inventor holds 24 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 12 EPO patents, primarily in Viral Replicon Systems. Top assignees: Alphavax, Incorporated, Janssen Pharmaceuticals, Inc., Harrisvaccines, Inc.. Active years: 2006-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Apex, NC (US) (2006 - 2019)
- San Diego, CA (US) (2019 - 2023)
- Olathe, KS (US) (2023)
Company Filing History:
9 out of 19 
8 out of 161 
4 out of 4 
Years Active: 2006-2025
Areas of Expertise:
Title: Innovator Spotlight: Kurt Iver Kamrud
Introduction
Kurt Iver Kamrud, based in Apex, North Carolina, has established himself as a prominent figure in the field of biotechnology and genetic engineering. With an impressive portfolio of 22 patents, Kamrud's work has significantly contributed to advancements in gene expression and immune response modulation.
Latest Patents
Kamrud's latest patents showcase his innovative approach to genetic research. One notable patent is focused on "Compositions and methods for enhancing gene expression." This invention involves nucleic acid molecules designed to regulate gene expression by incorporating structural elements from viral capsids. The discovery of utilizing elements like the Downstream Loop (DLP) from viral capsid proteins represents a breakthrough in enhancing gene regulation techniques.
Another significant patent by Kamrud is titled "Induce and enhance immune responses using recombinant replicon systems." This disclosure pertains to the employment of self-amplifying RNA molecules intended to bolster immune responses, particularly following vaccination or therapeutic interventions. His methods include prime-boost immunization regimens, which are pivotal for effectively inducing a robust immune response in subjects.
Career Highlights
Kamrud's career has included substantial roles at notable organizations such as Alphavax, Incorporated and Janssen Pharmaceuticals, Inc. His experiences in these companies have allowed him to foster a deep understanding of the intersection between pharmaceutical applications and genetic research.
Collaborations
Throughout his career, Kamrud has collaborated with distinguished colleagues, including Jonathan F. Smith and Nathaniel Stephen Wang. These partnerships have not only enriched his work but have also propelled innovative research initiatives within their respective fields.
Conclusion
Kurt Iver Kamrud continues to make significant strides in the world of biotechnology through his patented inventions and collaborative efforts. His commitment to enhancing gene expression and immune responses is indicative of how innovations in genetic engineering can lead to transformative advancements in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile